Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

  1. Kalincik, T.
  2. Brown, J.W.L.
  3. Robertson, N.
  4. Willis, M.
  5. Scolding, N.
  6. Rice, C.M.
  7. Wilkins, A.
  8. Pearson, O.
  9. Ziemssen, T.
  10. Hutchinson, M.
  11. McGuigan, C.
  12. Jokubaitis, V.
  13. Spelman, T.
  14. Horakova, D.
  15. Havrdova, E.
  16. Trojano, M.
  17. Izquierdo, G.
  18. Lugaresi, A.
  19. Prat, A.
  20. Girard, M.
  21. Duquette, P.
  22. Grammond, P.
  23. Alroughani, R.
  24. Pucci, E.
  25. Sola, P.
  26. Hupperts, R.
  27. Lechner-Scott, J.
  28. Terzi, M.
  29. Van Pesch, V.
  30. Rozsa, C.
  31. Grand'Maison, F.
  32. Boz, C.
  33. Granella, F.
  34. Slee, M.
  35. Spitaleri, D.
  36. Olascoaga, J.
  37. Bergamaschi, R.
  38. Verheul, F.
  39. Vucic, S.
  40. McCombe, P.
  41. Hodgkinson, S.
  42. Sanchez-Menoyo, J.L.
  43. Ampapa, R.
  44. Simo, M.
  45. Csepany, T.
  46. Ramo, C.
  47. Cristiano, E.
  48. Barnett, M.
  49. Butzkueven, H.
  50. Coles, A.
  51. Show all authors +
Journal:
The Lancet Neurology

ISSN: 1474-4465 1474-4422

Year of publication: 2017

Volume: 16

Issue: 4

Pages: 271-281

Type: Article

DOI: 10.1016/S1474-4422(17)30007-8 GOOGLE SCHOLAR